Literature DB >> 32723516

When and How to Diagnose Fabry Disease in Clinical Pratice.

Martin Michaud1, Wladimir Mauhin2, Nadia Belmatoug3, Roselyne Garnotel4, Naiya Bedreddine5, Florian Catros6, Sophie Ancellin6, Olivier Lidove2, Francis Gaches6.   

Abstract

Fabry disease is a frequent lysosomal storage disorder secondary to the deficiency of alpha-galactosidase A enzyme. This X-linked genetic disease realizes progressive and systemic manifestations that affect both male and female. Fabry disease may present as "classical", as "late-onset" or "non-classical" forms. Symptoms and organ involvements of classical Fabry disease are acral pain crisis, cornea verticillata, hypertrophic cardiomyopathy, stroke and chronic kidney disease with proteinuria. Other common symptoms are often poorly recognized, such as gastrointestinal or ear involvements. In classical Fabry disease, symptoms first appear during childhood or during teenage years in males, but later in females. Patients with non-classical or late-onset Fabry disease have delayed manifestations or a single-organ involvement. Diagnosis is therefore difficult when classical organ involvements are missing, in paucisymptomatic patients or in late-onset forms. Recognition of Fabry disease is important because effective treatments are available. They have to be prescribed early. In male, diagnosis is made with alpha-galactosidase A enzyme activity dosage in leukocyte, that is very low or null in classical forms and under 30 percent in late-onset forms. Diagnosis is more challenging in females who may express normal residual enzyme activity. Other plasmatic biomarkers, such as lyso-globotriaosylceramide are interesting, especially in females. In this review, we aimed to summarize main clinical manifestations of Fabry disease to know when to evoke Fabry disease and propose a practical diagnosis algorithm to know how to diagnose.
Copyright © 2020 Southern Society for Clinical Investigation. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Alpha galactosidase a; Fabry disease; Gla; Globotriaosylceramide; Hypertrophic cardiomyopathy

Year:  2020        PMID: 32723516     DOI: 10.1016/j.amjms.2020.07.011

Source DB:  PubMed          Journal:  Am J Med Sci        ISSN: 0002-9629            Impact factor:   2.378


  8 in total

1.  Late-onset Fabry disease due to a new (p.Pro380Leu) pathogenic variant of GLA Gene.

Authors:  Vittoria Cianci; Angelo Pascarella; Sara Gasparini; Vincenzo Donadio; Rocco Liguori; Alex Incensi; Carmelo Massimiliano Rao; Claudio Franzutti; Giuseppe Scappatura; Umberto Aguglia; Edoardo Ferlazzo
Journal:  Metab Brain Dis       Date:  2022-09-30       Impact factor: 3.655

2.  Aseptic meningitis in Fabry disease due to a novel GLA variant: an expanded phenotype?

Authors:  Paulo Ribeiro Nóbrega; João Lucas Araújo Morais; Alliane Milliane Ferreira; Alisson Dantas de Medeiros; Beatrice Araújo Duarte; Deborah Moreira Rangel; Fabrício Oliveira Lima; Anderson Rodrigues Brandão de Paiva; Luciana Paim-Marques; Fernando Kok; André Luiz Santos Pessoa; Pedro Braga-Neto; Fernanda Martins Maia Carvalho
Journal:  Neurol Sci       Date:  2022-09-12       Impact factor: 3.830

3.  Drug Repositioning for Fabry Disease: Acetylsalicylic Acid Potentiates the Stabilization of Lysosomal Alpha-Galactosidase by Pharmacological Chaperones.

Authors:  Maria Monticelli; Ludovica Liguori; Mariateresa Allocca; Andrea Bosso; Giuseppina Andreotti; Jan Lukas; Maria Chiara Monti; Elva Morretta; Maria Vittoria Cubellis; Bruno Hay Mele
Journal:  Int J Mol Sci       Date:  2022-05-04       Impact factor: 6.208

Review 4.  Pulvinar Sign, Stroke and Their Relationship with Fabry Disease: A Systematic Review and Metanalysis.

Authors:  Juan Fernando Ortíz; María Belén Solís; Syed Saad Ali; Mahika Khurana; Juan Andrés Moncayo; Nishel Yogesh Kothari; Mateo Alzamora; Ahmed Eissa-Garces; Ghanshyam Patel; Gustavo Andrés Monteros; Meghdeep Sen; Jonathan Quiñonez
Journal:  Neurol Int       Date:  2022-06-01

5.  LC-MS lipidomics of renal biopsies for the diagnosis of Fabry disease.

Authors:  Hoda Safari Yazd; Sina Feizbakhsh Bazargani; Christine A Vanbeek; Kelli King-Morris; Coy Heldermon; Mark S Segal; William L Clapp; Timothy J Garrett
Journal:  J Mass Spectrom Adv Clin Lab       Date:  2021-11-26

6.  Implications of Corneal Refractive Surgery in Patients with Fabry Disease.

Authors:  Majid Moshirfar; Nour Bundogji; Alyson N Tukan; Yasmyne C Ronquillo
Journal:  Ophthalmol Ther       Date:  2022-04-16

7.  Raloxifene induced keratopathy: A case report.

Authors:  Ji Min Park; Kyeong Do Jeong; Min-Ji Kang; Jee Hye Lee; Jae Suk Kim; Je Hyung Hwang
Journal:  Am J Ophthalmol Case Rep       Date:  2022-07-13

8.  A survey on the patient journey in Fabry disease in Japan.

Authors:  Mina Tsurumi; Asuka Ozaki; Yoshikatsu Eto
Journal:  Mol Genet Metab Rep       Date:  2022-08-17
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.